IDO1 and neoplasm: From these observations, we conclude that whereas IDO1 inhibitors were developed to reinvigorate immune cells in a TRP-deprived milieu, another consequence of TRP replenishment is that tumor cells are protected against T cell elimination or, in other words, an on-target adverse effect of IDO1 inhibition.